Detalhe da pesquisa
1.
Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
Future Oncol
; 20(13): 821-832, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38305004
2.
Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer.
Future Oncol
; 17(36): 5119-5127, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34698523
3.
Long-term Outcomes of Peripheral Blood Stem Cell Unrelated Donors Mobilized with Filgrastim.
Blood Adv
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38687368
4.
Two decades of pegfilgrastim: what have we learned? Where do we go from here?
Curr Med Res Opin
; 39(5): 707-718, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36976784
5.
Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb).
Ther Adv Med Oncol
; 15: 17588359231182386, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37360769
6.
Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US.
Ther Adv Med Oncol
; 13: 17588359211041961, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35003333